Compare OMDA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMDA | PSNL |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 897.6M | 746.8M |
| IPO Year | 2025 | 2019 |
| Metric | OMDA | PSNL |
|---|---|---|
| Price | $11.32 | $8.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $24.80 | $11.33 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $232,342,000.00 | $69,103,000.00 |
| Revenue This Year | $52.49 | N/A |
| Revenue Next Year | $22.68 | $19.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 89.23 | N/A |
| 52 Week Low | $10.28 | $2.83 |
| 52 Week High | $28.40 | $11.50 |
| Indicator | OMDA | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 25.95 | 47.65 |
| Support Level | $10.28 | $7.95 |
| Resistance Level | $12.05 | $9.04 |
| Average True Range (ATR) | 1.05 | 0.71 |
| MACD | -0.31 | -0.10 |
| Stochastic Oscillator | 14.38 | 39.47 |
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.